摘要
目的:探讨肝动脉化疗栓塞(TACE)联合经皮肝穿刺门静脉置管持续灌注华蟾素注射液治疗原发性肝癌的价值。方法:对16例确诊为原发性肝癌患者先在数字减彩血管造影(DSA)下行超选择性肝动脉化疗栓塞,术后予护肝等治疗,1周内在超声引导下行经皮肝穿刺门静脉置管持续灌注化疗,灌注药物为华蟾素注射液。间隔4-6周重复上述治疗,每例治疗2-3周期。结果:全组病例均获得随访,无手术死亡及严重并发症。3个月后随访表明近期疗效确切。经治疗后肿瘤完全坏死者6例(37.5%),明显缩小者5例(31.25%),稳定者2例(12.5%),无效3例(18.75%)。所有病例仍在跟踪随访中。结论:TACE联合门静脉置管持续灌注华蟾素注射液治疗能有效灭活和抑制肿瘤,在原发性肝癌的治疗中具有重要的临床价值。
Objective：To discuss the value of treating primary liver cancer by transcatheter arterial chemoembolization（TACE） with continuous infusing Huachansu Injection through a catheter placed in portal vein.Methods：16 Cases with primary liver cancer firstly accepted superselective TACE under DSA,then accepted therapy of protecting liver function.Within a week to give TACE with continuous infusing Huachansu Injection through a catheter placed in portal vein by the ultrasound-guided.Interval of 4 to 6 weeks to repeat the above-mentioned treatment,and the treatment of each case was 2-3 cycles.Results：The whole group of cases was followed up,and there was no operative death and severe complications.Follow-up after 3 months showed that the exact short-term effect.6 cases were completely tumor necrosis after treatment（37.5%）,5 cases were significantly improved（31.25%）,2 cases were stable,3 cases were invalid.All cases are still tracking follow-up.Conclusion：The treatment of primary liver cancer by TACE with continuous infusing Huachansu Injection through a catheter placed in portal vein can effectively inactivate and inhibit tumor,and had important clinical value in the treatment of primary liver cancer.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2010年第5期792-794,共3页
China Journal of Traditional Chinese Medicine and Pharmacy
关键词
TACE
门静脉置管
华蟾素注射液
原发性肝癌
Transcatheter arterial chemoembolization
Catheter Placed in portal vein
Huachansu Injection
Primary liver cancer
